Retrospective Analysis Of The Expression Of TopoIIα,ER,PR,Her-2,Ki-67 Before And After Neoadjuvant Chemotherapy In Breast Cancer

Ojective:observe the expression of TopoⅡα,ER,PR,Her-2 and Ki-67 before and after the neoadjuvant chemotherapy and analysis the neoadjuvant chemotherapy's effect on them. 2) to analysis the relevance between the biologic factors and the efficiency of the neoadjuvant chemotherapy.Methods:the cohort includes 57 patients with invasive breast cancer (phaseⅡa-Ⅳ) in the mastology department of Sichuan People's Hospital between January 2008 to April 2010, all of them received neoadjuvant chemotherapy. The pathologic samples were from the core needle biopsies and the operations.The expression of the biomarkers (TopoⅡα,ER,PR,Her-2 and Ki-67) is detected immunohistochemically before and after neoadjuvant chemotherapy. Clinical efficiency and the differences of expression of the biomarkers are assessed before and after the new adjuvant chemotherapy.Results:1)of all the 57 patients, the expression rates of the TopoⅡα,ER,PR,Her-2 and Ki-67 are 54.4%, 54.4%,49.1%,26.3%,71.9% respectively; after the neoadjuvant chemotherapy, the expression rates are 35.1%,80.1%,56.1%,17.5%,43.9% respectively. There is no significant difference of expression of PR and Her-2 before and after the neoadjuvant chemotherapy.2) Of all the patients, there were 2 cases of pCR(3.5%),2 cases of CR(3.5%) and 44 cases of PR(77.2%), the overall efficient rate is 80.7%.3) The diversions of the expression of TopoⅡα,ER and Ki-67 after neoadjuvant chemotherapy are relevant to the clinical efficiency, while there are no relevancy as for the PR and Her-2.Conclusion:1)The neoadjuvant chemotherapy has some effects on the expression of TopoⅡα,ER and Ki-67:the neoadjuvant chemotherapy can upgrade the expression of TopoⅡα,Ki-67 and downgrade the expression of ER.2) The expression of TopoⅡαand Ki-67 is relevant to the responsiveness to the neoadjuvant chemotherapy:the patients with TopoⅡα+ and ki-67 over expression are more responsive to and can get more benefit from the neoadjuvant chemotherapy.3) Most of the breast cancers are responsive to the neoadjuvant chemotherapy clinically and pathologically.4) The conclusion is just preliminary because of the retrospective study with a small cohort, prospective multi-central randomized controlled trials are needed to emphasis the conclusion.